IRF5 and breast carcinoma: Combined with recent data from screening human breast tumors for molecular signatures that revealed when IRF5 expression is retained, it encompasses a breast cancer signature that predicts increased survival and lower incidence of metastasis [29,30], these data suggest a functional and pathogenic consequence due to loss of IRF5 expression that relates to human mammary epithelial growth and metastasis.